Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gan & Lee Out-Licenses Ex-China Rights for Three Diabetes Biosimilars to Sandoz

publication date: Dec 19, 2018

China's Gan & Lee Pharma out-licensed ex-China rights to three insulin analogs to Sandoz, the generics division of Novartis. The three Gan & Lee products are biosimilars to glargine, lispro and aspart, which have combined global market sales of $12 billion. Sandoz will have commercialization rights to the biosimilars in most ex-China markets, including the EU, the US, Switzerland, Japan, South Korea, Canada, Australia and New Zealand markets. The financial terms of the agreement were not disclosed. Gan & Lee is based in Beijing. More details....

Stock Symbol: (NYSE: NVS)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital